
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the quarterly period ended: **June 30, 2016**

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the transition period from _____ to _____

Commission File Number: **000-53012**

FIRST CHOICE HEALTHCARE SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

90-0687379
(IRS Employer Identification No.)

709 S. Harbor City Boulevard, Suite 250, Melbourne, Florida 32901
(Address of principal executive offices)

(321) 725-0090
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 15, 2016, there were 24,238,613 shares outstanding of the registrant's Common Stock.

PART I.	<u>FINANCIAL INFORMATION</u>	3
ITEM 1	<u>Financial Statements</u>	3
	<u>Condensed consolidated balance sheets as of June 30, 2016 (unaudited) and December 31, 2015</u>	3
	<u>Condensed consolidated statements of operations for the three and six months ended June 30, 2016 and 2015 (unaudited)</u>	4
	<u>Condensed consolidated statement of stockholders' equity for the six months ended June 30, 2016 (unaudited)</u>	5
	<u>Condensed consolidated statements of cash flows for the six months ended June 30, 2016 and 2015 (unaudited)</u>	6
	<u>Notes to condensed consolidated financial statements (unaudited)</u>	7
ITEM 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	27
ITEM 3.	<u>Quantitative and Qualitative Disclosures about Market Risk</u>	35
ITEM 4.	<u>Controls and Procedures</u>	35
PART II.	<u>OTHER INFORMATION</u>	36
ITEM 1.	<u>Legal Proceedings</u>	36
ITEM 1A.	<u>Risk Factors</u>	36
ITEM 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	36
ITEM 3.	<u>Defaults Upon Senior Securities</u>	36
ITEM 4.	<u>Mine Safety Disclosures</u>	36
ITEM 5.	<u>Other Information</u>	36
ITEM 6.	<u>Exhibits</u>	36
	<u>SIGNATURES</u>	37

PART I

ITEM 1. FINANCIAL STATEMENTS

**FIRST CHOICE HEALTHCARE SOLUTIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS**

	June 30, 2016 <u>(unaudited)</u>	December 31, 2015 <u></u>
ASSETS		
Current assets		
Cash (amounts related to VIE of \$1,300,391 and \$1,556,303)	\$ 7,785,602	\$ 1,594,998
Cash-restricted	—	359,414
Accounts receivable, net (amounts related to VIE of \$5,324,747 and \$4,544,308)	8,369,428	6,623,894
Employee loans (amounts related to VIE of \$1,084,406 and \$636,293)	1,084,406	672,293
Prepaid and other current assets (amounts related to VIE of \$151,147 and \$183,465)	221,156	316,773
Capitalized financing costs, current portion (amounts related to VIE of \$-0- and \$1,317)	—	39,533
Total current assets	<u>17,460,592</u>	<u>9,606,905</u>
Property, plant and equipment, net of accumulated depreciation of \$1,058,933 and \$3,075,648 (amounts related to VIE of \$735,079 and \$773,808)	<u>2,644,783</u>	<u>8,613,502</u>
Other assets		
Goodwill (amount relating to VIE of \$899,465)	899,465	899,465
Deferred costs, net of amortization of \$376,418 and \$215,096	2,850,009	3,011,331
Patient list, net of accumulated amortization of \$85,000 and \$75,000	215,000	225,000
Patents, net of accumulated amortization of \$47,750 and \$38,200	238,750	248,300
Investments (amounts related to VIE of \$22,005 and \$16,914)	22,005	16,914
Deferred tax asset	181,029	—
Deposits	16,071	2,571
Total other assets	<u>4,422,329</u>	<u>4,403,581</u>
Total assets	<u>\$ 24,527,704</u>	<u>\$ 22,623,988</u>
LIABILITIES AND EQUITY		
Current liabilities		
Accounts payable and accrued expenses (amounts related to VIE of \$2,278,994 and \$2,319,056)	\$ 3,305,834	\$ 3,937,244
Accounts payable, related party (amount related to VIE of \$251,588)	251,588	251,588
Stock based payable	601,833	1,198,900
Advances	—	43,082
AMT tax payable	181,029	—
Settlement payable	—	600,000
Line of credit, short term (amount related to VIE of \$439,524 and \$416,888)	2,939,524	2,566,888
Note payable, related party, current portion (amount related to VIE of \$-0- and \$428,645)	—	428,645
Notes payable, current portion (amount related to VIE of \$4,128 and \$10,341)	513,506	7,652,941
Unearned revenue	26,354	42,704
Deferred rent, short term portion (amount related to VIE of \$237,620 and \$118,810)	237,620	118,810
Total current liabilities	<u>8,057,288</u>	<u>16,840,802</u>
Long term debt:		
Deposits held	58,234	67,432
Notes payable, long term portion	275,125	535,822
Deferred rent, long term portion (amount related to VIE of \$2,141,198 and \$2,141,199)	2,167,427	2,141,199
Total long term debt	<u>2,500,786</u>	<u>2,744,453</u>
Total liabilities	<u>10,558,074</u>	<u>19,585,255</u>
Equity		
Preferred stock, \$0.01 par value; 1,000,000 shares authorized, Nil issued and outstanding	—	—
Common stock, \$0.001 par value; 100,000,000 shares authorized, 24,238,613	—	—

and 22,867,626 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively	24,239	22,868
Common stock subscription	—	175,000
Additional paid in capital	22,393,921	21,196,792
Accumulated deficit	<u>(9,554,839)</u>	<u>(19,274,917)</u>
Total stockholders' equity attributable to First Choice Healthcare Solutions, Inc.	12,863,321	2,119,743
Non-controlling interest (note 15)	<u>1,106,309</u>	<u>918,990</u>
Total equity	<u>13,969,630</u>	<u>3,038,733</u>
Total liabilities and equity	<u>\$ 24,527,704</u>	<u>\$ 22,623,988</u>

See the accompanying notes to these unaudited condensed consolidated financial statements

FIRST CHOICE HEALTHCARE SOLUTIONS, INC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	Three months ended June 30,		Six months ended June 30,	
	2016	2015	2016	2015
Revenues:				
Patient service revenue	\$ 7,290,456	\$ 3,810,299	\$ 14,168,121	\$ 6,095,587
Provision for bad debts	(267,194)	(6,260)	(529,718)	(51,484)
Net patient service revenue less provision for bad debts	7,023,262	3,804,039	13,638,403	6,044,103
Rental revenue	629,838	520,276	1,256,450	785,379
Total revenue	7,653,100	4,324,315	14,894,853	6,829,482
Operating expenses:				
Salaries and benefits	3,139,042	2,125,481	5,919,611	3,071,601
Other operating expenses	1,573,376	563,422	2,760,650	1,014,907
General and administrative	2,535,741	1,649,870	4,941,618	2,203,154
Depreciation and amortization	136,800	144,417	435,750	284,926
Total operating expenses	7,384,959	4,483,190	14,057,629	6,574,588
Net income (loss) from operations	268,141	(158,875)	837,224	254,894
Other income (expense):				
Gain on sale of property and improvements	23,378	—	9,212,346	—
Miscellaneous income (expense)	46,812	40,369	105,669	41,119
Amortization financing costs	(329)	(19,229)	(15,654)	(39,915)
Interest expense, net	(51,053)	(358,994)	(232,188)	(722,138)
Total other expense	18,807	(337,854)	9,070,173	(720,934)
Net income (loss) before provision for income taxes	286,949	(496,729)	9,907,397	(466,040)
Income taxes (benefit)	—	—	—	—
Net income (loss)	286,949	(496,729)	9,907,397	(466,040)
Non-controlling interest (note 15)	(133,812)	—	(187,319)	—
NET INCOME (LOSS) ATTRIBUTABLE TO FIRST CHOICE HEALTHCARE SOLUTIONS, INC.	\$ 153,137	\$ (496,729)	\$ 9,720,078	\$ (466,040)
Net income (loss) per common share, basic	\$ 0.01	\$ (0.03)	\$ 0.42	\$ (0.03)
Net income (loss) per common share, diluted	\$ 0.01	\$ (0.03)	\$ 0.36	\$ (0.03)
Weighted average number of common shares outstanding, basic	23,862,943	18,999,475	23,374,625	18,533,559
Weighted average number of common shares outstanding, diluted	27,196,277	18,999,475	26,707,959	18,533,559

See the accompanying notes to these unaudited condensed consolidated financial statements

FIRST CHOICE HEALTHCARE SOLUTIONS, INC.
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY
SIX MONTHS ENDED JUNE 30, 2016
(unaudited)

	Common stock		Additional	Common	Accumulated	Non-	Total
	Shares	Amount	Paid in Capital	Stock Subscriptions	Deficit	controlling Interest	
Balance, December 31, 2015	22,867,626	\$22,868	\$21,196,792	\$ 175,000	\$(19,274,917)	\$ 918,990	\$ 3,038,733
Common stock issued in connection with loan extension	100,000	100	91,900	—	—	—	92,000
Common stock issued in settlement of common stock subscription	129,630	130	174,870	(175,000)	—	—	—
Common stock issued for services rendered	1,141,357	1,141	930,359	—	—	—	931,500
Net income	—	—	—	—	9,720,078	187,319	9,907,397
Balance, June 30, 2016	<u>24,238,613</u>	<u>\$24,239</u>	<u>\$22,393,921</u>	<u>\$ —</u>	<u>\$ (9,554,839)</u>	<u>\$1,106,309</u>	<u>\$13,969,630</u>

See the accompanying notes to these unaudited condensed consolidated financial statements

FIRST CHOICE HEALTHCARE SOLUTIONS, INC
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

	Six months ended June 30,	
	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Income (loss)	\$ 9,907,397	\$ (466,040)
Adjustments to reconcile net income (loss) to cash (used in) provided by operating activities:		
Depreciation and amortization	435,750	338,700
Amortization of financing costs	15,654	39,915
Bad debt expense	529,718	51,484
Gain on sale of property	(9,212,346)	—
Common stock issued in connection with loan extension	92,000	227,000
Stock based compensation	334,433	139,750
Changes in operating assets and liabilities:		
Accounts receivable	(2,275,252)	(556,635)
Prepaid expenses and other	95,617	237,431
Restricted funds	359,414	(54,563)
Employee loans	(412,113)	(103,654)
Accounts payable and accrued expenses	(650,425)	160,359
Settlement payable	(600,000)	—
Deposits	(22,698)	(5,469)
Deferred rent	145,038	39,603
Unearned income	(16,350)	22,113
Net cash (used in) provided by operating activities	(1,274,163)	69,994
CASH FLOWS FROM INVESTING ACTIVITIES:		
Cash from variable interest entity	—	679,673
Proceeds from sale of property	15,113,497	—
Purchase of equipment	(149,507)	(40,065)
Net cash provided by investing activities	14,963,990	639,608
CASH FLOWS FROM FINANCING ACTIVITIES:		
(Repayments) proceeds from advances	(43,082)	129,000
Proceeds from lines of credit	372,636	355,656
Net payments on notes payable	(7,828,777)	(418,780)
Net cash (used in) provided by financing activities	(7,499,223)	65,876
Net increase in cash and cash equivalents	6,190,604	775,478
Cash and cash equivalents, beginning of period	1,594,998	279,087
Cash and cash equivalents, end of period	<u>\$ 7,785,602</u>	<u>\$ 1,054,565</u>
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:		
Cash paid during the period for interest	<u>\$ 237,943</u>	<u>\$ 594,211</u>
Cash paid during the period for taxes	<u>\$ —</u>	<u>\$ —</u>
Supplemental Disclosure on non-cash investing and financing activities:		
Common stock issued in settlement of accrued expenses	<u>\$ 597,067</u>	<u>\$ 15,000</u>
Common stock issued in settlement of convertible note and interest	<u>\$ —</u>	<u>\$ 811,200</u>
Fair value of options issued to acquire management control of variable interest entity	<u>\$ —</u>	<u>\$ 3,226,427</u>

See the accompanying notes to these unaudited condensed consolidated financial statements

NOTE 1 —BASIS OF PRESENTATION

A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:

General

The (a) condensed consolidated balance sheet as of December 31, 2015, which has been derived from the audited financial statements of First Choice Healthcare Solutions, Inc. (“FCHS” and including, where appropriate, its consolidated subsidiaries and entities in which we have a controlling financial interest, the “Company”), and (b) the unaudited condensed consolidated interim financial statements as of June 30, 2016 of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. To determine if we hold a controlling financial interest in an entity, we first evaluate if we are required to apply the variable interest entity (“VIE”) model to the entity, otherwise the entity is evaluated under the voting interest model.

Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2016. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2016.

Basis of Presentation

Effective April 4, 2012, Medical Billing Assistance, Inc., a Colorado corporation (“Medical Billing”), merged with and into the Company. The effect of the merger was that Medical Billing reincorporated from Colorado to Delaware (the “Reincorporation”). The Company is deemed to be the successor issuer of Medical Billing under Rule 12g-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

As a result of the Reincorporation, the Company changed its name to First Choice Healthcare Solutions, Inc. and its shares underwent an effective four-for-one reverse split. Other than the foregoing, the Reincorporation did not result in any change in the business, management, fiscal year, accounting, and location of the principal executive offices, assets or liabilities of the Company.

On April 2, 2012, the Company, through its wholly owned subsidiary FCID Medical, Inc., completed its acquisition of First Choice Medical Group of Brevard, LLC (“First Choice – Brevard”), pursuant to the Membership Interest Purchase Closing Agreement (the “Purchase Agreement”). The Company has been managing the practice of First Choice – Brevard since November 1, 2011, pursuant to a Management Services Agreement.

Brevard Orthopaedic Spine & Pain Clinic, Inc.

Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operation and Control Agreement (the “Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations, including the requirement to absorb losses or right to receive economic benefits. The initial term of the Agreement expires on December 31, 2016 with an option by the Company to extend the term until December 31, 2023.

The Agreement allows the Company to hold the current or potential rights that give it the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance, combined with a variable interest that gives the Company the right to receive potentially significant benefits or the obligation to absorb potentially significant losses. The Company has a controlling financial interest in the VIE. Rights held by others to remove the party with power over the VIE are not considered unless one party can exercise those rights unilaterally. When changes occur to the structure of the entity, the Company will reconsider whether it is subject to the VIE model. The Company continuously evaluates whether it has a controlling financial interest in the VIE.

Crane Creek Surgery Center

Effective October 1, 2015, the Company, through its recently formed wholly owned subsidiary, CCSC Holdings, Inc., acquired a 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of \$560,000 comprised of \$140,000 cash and a promissory note for \$420,000, which bears 8% interest per annum, matures April 15, 2016 and was personally guaranteed by the Company’s Chief Executive Officer. This note was paid in full on April 15, 2016. In connection with the investment, the Company is entitled to 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crane Creek.

The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries FCID Holdings, Inc.; MTMC of Melbourne, Inc.; Marina Towers, LLC; FCID Medical Inc.; TBC Holdings of Melbourne, Inc.; First Choice – Brevard; Surgical Partners of Melbourne, Inc. and CCSC Holdings, Inc., along with The B.A.C.K. Center and Crane Creek, our variable interest entities (“VIE”). All significant intercompany balances and transactions, including those involving the VIE, have been eliminated in consolidation.

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES

Use of estimates

The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, and stock-based compensation. Actual results may differ from these estimates.

Revenue recognition

The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, “*Revenue Recognition*” (“ASC 605-10”), which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, “*Multiple-Element Arrangements*” (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. The effect of implementing ASC 605-25 on the Company’s financial position and results of operations was not significant.

The Company recognizes in accordance with Accounting Standards Codification subtopic 954-310, “*Health Care Entities*” (“ASC 954-310”), significant patient service revenue at the time the services are rendered, even though it does not assess the patient’s ability to pay. Therefore, The Company’s interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Company’s reports. These estimates are based upon the past history and identified trends for each of our payers.

Patient service revenue

The Company recognizes patient service revenue associated with services provided to patients who have third-party payer coverage on the basis of contractual rates for the services provided. For uninsured or self-pay patients that do not qualify for charity care, the Company recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a portion of the Company’s patient service revenue may be potentially uncollectible due to patients who are unable or unwilling to pay for the services provided or the portion of their bill for which they are responsible. Thus, the Company records a provision for bad debts related to potentially uncollectible patient service revenue in the period the services are provided.

Rental revenue

FCID Holdings had one real estate holding, Marina Towers, a Class A 78,000 square foot, six-story building located on the Indian River in Melbourne, Florida. The address is 709 South Harbor City Boulevard, Melbourne, Florida 32901. In addition to housing our corporate headquarters and First Choice Medical Group, the building, which averages 95% annual occupancy, also leases commercial office space to tenants. Our corporate headquarters currently utilize 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.

On March 31, 2016, we completed the sale of Marina Towers to Global Medical REIT Inc. for a purchase price of \$15.45 million. In addition, our wholly owned subsidiary, Marina Towers, LLC, leased back the entire facility via a 10-year absolute triple-net master lease agreement that will expire in 2026 and be renewable for two five-year periods on the same terms and conditions as the primary lease term with the exception of rent, which will be adjusted to the prevailing market rent at renewal and will escalate in successive years during the extended lease period.

Until Marina Towers' sale on March 31, 2016, the Company recognized rental revenue associated with the period of time the facility is leased at the contractual lease rates (or on the basis of discounted rates, if negotiated).

In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases approximately 34,480 square feet of commercial office space to third party tenants at 2222 South Harbor City Boulevard, Melbourne, Florida 32901, which is also The B.A.C.K. Center's main medical practice location.

Cash

Cash consists of cash held in bank demand deposits. The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. As of June 30, 2016, the Company had \$7,785,602 cash, of which \$1,300,391 held by VIE. As of December 31, 2015, the Company had \$1,594,998 cash, of which \$1,556,303 held by VIE.

Concentrations of credit risk

The Company's financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company's cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

Accounts receivables

Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its past history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts.

- Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account and provision of bad debts.
- Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts.

As of June 30, 2016 and December 31, 2015, the Company's provision for bad debts was \$3,322,240 and \$2,498,398, respectively.

Segment information

Accounting Standards Codification subtopic "*Segment Reporting*" 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company's principal operating segments (see Note 17 – Segment Information).

Patents

Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company's intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 shares of the Company's common stock to a related party. The shares of common stock were valued at \$286,500, which was estimated to be approximately the fair value of the patent acquired and did not materially differ from the fair value of the common stock. The amortization for the three and six months ended June 30, 2016 was \$4,775 and \$9,550, respectively; and for the three and six months ended June 30, 2015 was \$4,775 and \$9,550, respectively. Accumulated amortization of Patent costs were \$47,750 and \$38,200 at June 30, 2016 and December 31, 2015, respectively.

Patient list

Patient list is comprised of acquired patients in connection with the acquisition of First Choice - Brevard and is amortized ratably over the estimated useful life of 15 years. The amortization for the three and six months ended June 30, 2016 was \$5,000 and \$10,000, respectively; and for the three and six months ended June 30, 2015 was \$5,000 and \$10,000, respectively. Accumulated amortization of patient list costs were \$85,000 and \$75,000 at June 30, 2016 and December 31, 2015, respectively.

Net income per share

The Company computes basic net income per share by dividing net income per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the "treasury stock" and/or "if converted" methods as applicable. The computation of basic and diluted income per share for the three and six months ended June 30, 2016 and 2015 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net income per share are as follows:

	June 30, 2016	June 30, 2015
Convertible notes payable	—	2,990,920
Warrants to purchase common stock	4,324,630	4,195,000
Options to purchase common stock	3,000,000	3,000,000
Restricted stock awards	150,000	
Totals	<u>7,474,630</u>	<u>10,185,920</u>

Stock-based compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations, as if such amounts were paid in cash.

Deferred costs

On May 1, 2015, in connection with the Operation and Control Agreement with Brevard Orthopaedic Spine & Pain Clinic, Inc. ("The B.A.C.K. Center"), the Company reserved 3,000,000 options to purchase the Company's common stock at \$1.35 per share, expiring on December 31, 2023 and vesting is contingent on The B.A.C.K. Center employees executing employment agreements with TBC Holding and the acquisition of the variable interest entity. The determined fair value of \$3,226,427, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 134.09% and Risk free rate: 2.12%, is amortized ratably to operations over an estimated 8.67-year life. The amortization for the three and six months ended June 30, 2016 was \$80,661 and \$161,322; and for the three and six months ended June 30, 2015 was \$53,774. Accumulated amortization of the deferred costs was \$376,418 and \$215,096 at June 30, 2016 and December 31, 2015, respectively.

Investments

The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures ("ASC 323-10), which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company owned a 0.6660% interest in a non-consolidated affiliate, Doctor's Surgical Partnership, LTD. In accordance with the equity method of accounting, investments in non-consolidated affiliates are carried at cost and adjusted for the Company's proportionate share of their undistributed earnings or losses.

Income Taxes

The Company accounts for income taxes pursuant to Accounting Standards Codified 740 (“ASC 740”). Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Fair value

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

- Level 1 - Quoted prices in active markets for identical assets or liabilities.
- Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
- Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

The carrying value of the Company’s cash, accounts receivable, accounts payable, short-term borrowings (including lines of credit and notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity.

As of June 30, 2016 and December 31, 2015, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.

Recent accounting pronouncements

There are other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Subsequent events

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed.

NOTE 3 – LIQUIDITY

The Company incurred various non-recurring expenses in 2015 in connection with the planned development of its Healthcare Services Business. Management believes the continuing trend of positive growth before interest, taxes, depreciation and amortization in 2016 will support improved liquidity. In 2015, the Company converted to equity a total of \$2,892,314 in outstanding debt, advances and accrued interest. Currently, the Company has four main sources of liquidity, its line of credit with CT Capital, LP; patient service revenue received from FCID Medical, Inc., TBC Holdings of Melbourne, Inc. and CCSC Holdings, Inc.; and rental revenue received from its real estate interests, FCID Holdings, Inc. and TBC Holdings of Melbourne, Inc.

On June 13, 2013, the Company's subsidiary, First Choice – Brevard entered into a loan and security agreement with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership for an accounts receivable line of credit in the maximum aggregate amount of \$1,500,000. Under the line of credit with CT Capital, the Company reduced the annual interest rate from 12% per annum to 6% per annum in exchange for the issuance to CT Capital of 100,000 restricted shares of the Company's common stock. On June 9, 2015, First Choice – Brevard entered into a modification agreement amending the loan and security agreement, increasing the maximum aggregate amount available from \$1,500,000 to \$2,000,000 and on December 14, 2015, increasing the maximum aggregate available from \$2,000,000 to \$2,500,000 and extending the maturity date to July 30, 2017 in exchange for 100,000 restricted shares of the Company's common stock. The \$500,000 increase may be repaid at any time, and is not subject to the conversion provision set forth in the loan agreement. All other terms and conditions of the loan agreement remain in full force and effect. As of June 30, 2016, the Company had used \$2,500,000 of the amount available under the line of credit. (See Note 6 – Lines of Credit).

FCID Holdings had one real estate holding, Marina Towers, a Class A 78,000 square foot, six-story building located on the Indian River in Melbourne, Florida. The address is 709 South Harbor City Boulevard, Melbourne, Florida 32901. In addition to housing our corporate headquarters and First Choice Medical Group, the building, which averages 95% annual occupancy, also leases commercial office space to tenants. Our corporate headquarters currently utilizes 2,521 square feet on the fifth floor of Marina Towers; and First Choice Medical Group, including its MRI center and Physical Therapy center, currently occupies 26,838 square feet on the ground, first and second floors. Until March 2016, Marina Towers was owned by Marina Towers, LLC, a subsidiary owned by FCID Holdings (99%) and MTMC of Melbourne, Inc. (1%), both wholly owned subsidiaries of the Company.

On March 31, 2016, we completed the sale of Marina Towers to Global Medical REIT Inc. for a purchase price of \$15.45 million. In addition, our wholly owned subsidiary, Marina Towers, LLC, leased back the entire facility via a 10-year absolute triple-net master lease agreement that will expire in 2026 and be renewable for two five-year periods on the same terms and conditions as the primary lease term with the exception of rent, which will be adjusted to the prevailing market rent at renewal and will escalate in successive years during the extended lease period. Until Marina Towers' sale on March 31, 2016, the Company recognized rental revenue associated with the period of time the facility is leased at the contractual lease rates (or on the basis of discounted rates, if negotiated).

In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases 31,835 square feet of commercial office space to third party tenants as of June 30, 2016.

The Company believes that the current positive cash balance, along with continued execution of its business development plan and the sale and leaseback of Marina Towers, will allow the Company to further improve its working capital and currently anticipates that it will have sufficient capital resources to meet projected cash flow requirements through the date that is one year and one day from the filing of this report.

However, in order to execute the Company's business development plan, which there can be no assurance we will achieve, the Company may need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and potentially reduce operating expenditures. If the Company is unable to secure additional capital, it may be required to curtail its business development initiatives and take additional measures to reduce costs in order to conserve its cash.

NOTE 4 — PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment at June 30, 2016 and December 31, 2015 are as follows:

	June 30, 2016	December 31, 2015
Land	\$ —	\$ 1,000,000
Building	—	3,055,168
Building improvements	183,713	4,211,749
Computer equipment	351,644	340,065
Medical equipment	2,908,218	2,822,027
Office equipment	260,141	260,141
	<u>3,703,716</u>	<u>11,689,150</u>
Less: accumulated depreciation	<u>(1,058,933)</u>	<u>(3,075,648)</u>
	<u>\$ 2,644,783</u>	<u>\$ 8,613,502</u>

During the three and six months ended June 30, 2016, depreciation expense charged to operations was \$46,364 and \$254,878, respectively; and during the three and six months ended June 30, 2015, depreciation expense charged to operations was \$134,642 and \$265,376, respectively.

During the six months ended June 30, 2016, the Company sold equipment for proceeds of \$45,000, recognizing a gain on sale of equipment of \$23,378.

Sale/Leaseback

On March 31, 2016, the Company sold Marina Towers, a 78,000 square-foot medical office building for a purchase price of \$15.45 million to Global Medical REIT Inc. The acquisition includes the site and building, an easement on the adjacent property to the north for surface parking, all tenant leases, and above and below ground garages (the "Property").

The entire facility was leased back to Marina Towers, LLC, a wholly owned subsidiary of the Company, via a 10-year absolute triple-net master lease agreement that expires in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions as the primary non-revocable lease term with the exception of rent, which will be adjusted to the prevailing fair market rent at renewal and will escalate in successive years during the extended lease period. The Company does not have any residual interest nor the option to repurchase the facility at the end of the lease term.

The lease is classified as an operating lease and as such recorded a gain on sale of property of \$9,188,968 during the six months ended June 30, 2016.

The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:

Six months ended December 31, 2016	\$ 552,338
Year ended December 31, 2017	1,121,245
Year ended December 31, 2018	1,143,670
Year ended December 31, 2019	1,166,543
Year ended December 31, 2020	1,189,874
Year ended December 31, 2021 and thereafter	6,646,044
	<u>\$ 11,819,714</u>

For the six months ended June 30, 2016, the Company collected \$535,999 in net rental revenue from third party tenants of Marina Towers.

NOTE 5 — ADVANCES

At June 30, 2016 and December 31, 2015, the Company received an aggregate of \$-0- and \$43,082, respectively, as cash advances from non-related parties. The advances are due upon demand with an interest rate of 12% per annum.

NOTE 6 — LINES OF CREDIT

Line of credit, CT Capital

On June 13, 2013, the Company's subsidiary, First Choice – Brevard entered into a loan and security agreement (the "Loan Agreement") with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership (the "Lender"). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of \$1,500,000 to First Choice - Brevard with an interest rate of 12% per annum (the "Loan"). The maturity date of the Loan is December 31, 2016. Interest is due and payable monthly. Upon default, the interest may be adjusted to the highest rate permissible by law. The Loan is secured by the accounts receivable and assets of the Company's subsidiary, First Choice – Brevard, which constitute the collateral for the repayment of the Loan. The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by legal letters of protection. At any time up until December 31, 2016, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of \$0.75 per share. The Company did not record an embedded beneficial conversion feature in the note since the fair value of the common stock did not exceed the conversion rate at the date of commitment.

On November 8, 2013, in consideration for the issuance of 100,000 restricted shares of the Company's common stock, the Lender agreed to modify its Loan. Under the Loan Agreement, as amended, the annual rate of interest of the Loan was reduced from 12% per annum to 6% per annum and will remain at 6% until November 1, 2015. All other terms under the Loan Agreement remain the same.

On June 9, 2015, First Choice – Brevard and the Lender entered into a Modification Agreement (“Modification”) further amending the Loan Agreement dated June 13, 2013, thereby increasing the Company's accounts receivable line of credit from \$1,500,000 to \$2,000,000. All of the other terms and conditions of the Loan Agreement, as amended, remain in full force and effect.

On December 14, 2015, First Choice-Brevard entered into a Modification Agreement (“Modification”) amending the Loan and Security Agreement dated June 13, 2013. The Modification Agreement increased the Company's accounts receivable line of credit from \$2,000,000 to \$2,500,000 and extended the maturity date of the Loan Agreement to June 30, 2017 (“Maturity Date”). In addition, the Company agreed to maintain an outstanding balance of not less than \$1,000,000 until the Maturity Date (“Minimum Borrowing”) and provide sixty (60) days prior written notice to prepay up to \$1,000,000 of the outstanding indebtedness in excess of the Minimum Borrowing. All of the other terms and conditions of the Loan Agreement remain in full force and effect.

In consideration of the \$500,000 increase in the accounts receivable line of credit, the Company issued the Lender 100,000 shares of its common stock, valued at \$92,000. The \$500,000 increase may be repaid by the Company at any time, and is not subject to the conversion provisions set forth in the Loan Agreement. The shares were accrued for as of December 31, 2015 and issued in the current quarter.

The obligations of the Company under the Loan Agreement, as amended, are guaranteed by certain affiliates of the Company, including a personal guarantee issued by the Company's Chief Executive Officer.

As of June 30, 2016 and December 31, 2015, the outstanding balance was \$2,500,000 and \$2,150,000, respectively.

Line of credit, Florida Business Bank

On June 27, 2012, The B.A.C.K. Center entered into a Promissory Note (the “Loan Agreement”) with Florida Business Bank, a Florida banking corporation (the “Lender”). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of \$1,000,000, with an interest rate of Prime floating plus 1.0%, as published in *The Wall Street Journal*, with a floor of 4.50% per annum (the “Loan”).

The Loan was modified on April 9, 2013, allowing a temporary increase to \$1,383,000 and allowing for a one-time draw of up to \$995,000 to be distributed to the shareholders for the purposes of financing the capitalization of TBC Equipment Leasing, LLC. The one-time draw was repaid within 45 days and the availability under the Loan returned to \$1,000,000. The modification allows for an interest rate of one month Libor floating plus 2.75%, as published in *The Wall Street Journal*, with a floor of 2.96% per annum.

Interest shall be due and payable monthly and principal is due on demand. The outstanding principal balance plus all accrued but unpaid interest shall be due on demand (the “Maturity Date”). Upon default, the interest may be adjusted to the highest rate permissible by law.

The Loan is secured by all assets of The B.A.C.K. Center now owned or hereafter acquired. The assets constitute the collateral for the repayment of the Loan.

The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 60% of eligible accounts receivables. Eligible receivables include all Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50. As of June 30, 2016, The B.A.C.K. Center had not violated the loan covenants.

The obligations of The B.A.C.K. Center under the Loan Agreement are guaranteed by the shareholders of The B.A.C.K. Center. The Loan Agreement is also guaranteed in the amount of \$950,000 by related parties of The B.A.C.K. Center. As of June 30, 2016 and December 31, 2015, the outstanding balance on the Loan was \$439,524 and \$416,888, respectively.

NOTE 7 — SETTLEMENT PAYABLE

On November 2, 2015, the Company and MedTRX Collection Services, Inc. signed a settlement and mutual release agreement, whereby the parties have agreed to settle all disputes and the pending arbitration actions and release each other from all claims, counterclaims, liabilities and obligations, except for obligations stipulated in the settlement or as otherwise reserved.

In connection with the settlement, on November 6, 2015, the Company issued two non-interest bearing promissory notes in aggregate of \$650,000, due the earlier of a) April 2, 2016, b) the date real estate (as identified) is sold, financed or transferred or c) date the stock payment (as described above) is redeemed. As of June 30, 2016 and December 31, 2015, the balance due on outstanding settlement promissory notes was \$-0- and \$600,000, respectively. The Company paid the notes in full on April 1, 2016.

NOTE 8 — NOTE PAYABLE, RELATED PARTY

Effective October 1, 2015, the Company acquired a 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of \$560,000 comprised of \$140,000 cash and a promissory note for \$420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Company’s Chief Executive Officer. The promissory note was issued to certain equity owners of The B.A.C.K. Center, an entity consolidated with the Company under VIE accounting. The outstanding principal and interest at June 30, 2016 and December 31, 2015 was \$-0- and \$428,645, respectively. This note was paid in full on April 15, 2016.

NOTE 9— NOTES PAYABLE

Notes payable as of June 30, 2016 and December 31, 2015 are comprised of the following:

	June 30, 2016	December 31, 2015
Mortgage Payable	\$ —	\$ 7,153,262
Note Payable, GE Capital (MRI)	645,426	844,098
Note Payable, GE Capital (X-ray)	73,285	97,232
Note Payable, GE Arm	54,500	67,455
Capital Lease Equipment	15,420	26,716
	<u>788,631</u>	<u>8,188,763</u>
Less current portion	<u>(513,506)</u>	<u>(7,652,941)</u>
	\$ 275,125	\$ 535,822

Mortgage payable

On August 12, 2011, the Company refinanced its existing mortgage note payable providing additional working capital funds. The aggregate amount of the note of \$7,550,000 with 6.10% interest per annum with monthly payments of \$45,753 beginning in October 2011 based on a 30-year amortization schedule with all remaining principal and interest due in full on September 16, 2016. The note is secured by land and the building along with first priority assignment of leases and rents. In connection with the sale/leaseback transaction (See Note 4), the Company paid off the outstanding balance on March 31, 2016.

Note payable — equipment financing

On May 21, 2012, the Company entered into a note payable with GE Healthcare Financial Services (“GE Capital”) in the amount of approximately \$2.4 million for equipment financing.

On September 27, 2012, the Company accepted the delivery of MRI equipment under the equipment finance lease. As such, the component price accepted of \$1,771,390 is due over 60 months and the associated monthly payment is \$0 for the first three months and \$38,152 per month for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the equipment finance lease to interest only payments of \$11,779 for the first three months and \$38,152 per month for the remaining monthly payments.

On August 22, 2012, the Company accepted the delivery of X-ray equipment under the equipment finance lease. As such, the component price accepted of \$212,389 is due over 60 months and the associated monthly payment is \$0 for the first three months and \$4,300 per month for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the equipment finance lease to interest only payments of \$1,384 for the first three months and \$4,575 per month for the remaining monthly payments.

On February 25, 2013, the Company accepted the delivery of C-arm equipment under the equipment finance lease. As such, the component price accepted of \$124,797 is due over 63 months and the associated monthly payment is \$0 for the first three months and \$2,388 for the remaining 60 months, including interest at 7.39% per annum.

Capital leases — equipment

On June 11, 2013, the Company entered into a lease agreement to acquire equipment with 48 monthly payments of \$956 payable through June 1, 2017 with an effective interest rate of 14.002% per annum. The Company may elect to acquire the leased equipment at a nominal amount at the end of the lease.

On October 25, 2011, The B.A.C.K. Center entered into a lease agreement to acquire equipment with 60 monthly payments of \$1,036 payable through October 26, 2016, with no stated interest rate. The B.A.C.K. Center may elect to acquire the leased equipment at a nominal amount at the end of the lease.

Aggregate principal maturities of long-term debt as of June 30, 2016:

	Amount
Six months ended December 31, 2016	\$ 254,648
Year ended December 31, 2017	521,447
Year ended December 31, 2018	12,536
Total	\$ 788,631

NOTE 10 — RELATED PARTY TRANSACTIONS

Effective October 1, 2015, the Company acquired a 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of \$560,000 comprised of \$140,000 cash and a promissory note for \$420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Company’s Chief Executive Officer. The promissory note was issued to certain equity owners of The B.A.C.K. Center, an entity consolidated with the Company under VIE accounting. This note was paid in full on April 15, 2016.

As of March 31, 2016, the Company received an aggregate of \$133,796 as cash advances from related parties. The advances were due upon demand with an interest rate of 12% per annum. On April 6, 2016, the Company paid the advances in full.

NOTE 11 — CAPITAL STOCK

During the six months ended June 30, 2016, the Company issued an aggregate of 100,000 shares of its common stock in connection with an increase in credit line, valued at \$92,000. (see Note 6 – Lines of Credit.)

During the six months ended June 30, 2016, the Company issued an aggregate of 1,141,357 shares of its common stock to officers, employees and service providers at an aggregate fair value of \$931,500, of which \$597,067 was expensed in 2015.

During the six months ended June 30, 2016, the Company issued an aggregate of 129,630 shares of its common stock in connection with settlement of a stock subscription from 2015 at an aggregate fair value of \$175,000.

Stock-based payable

The Company was obligated to issue its common stock to officers and consultants for past and future services as of June 30, 2016. The estimated liability as of June 30, 2016 of \$601,833 (\$0.89 per share) was determined based on services rendered. The shares were issued in reliance upon the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).

NOTE 12 — STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS

Options

The following table presents information related to stock options at June 30, 2016:

	Options Outstanding			Exercisable Number of Options
	Exercise Price	Number of Options	Weighted Average Remaining Life in Years	
\$	1.35	3,000,000	7.50	—

Transactions involving stock options issued are summarized as follows:

	Number of Shares	Weighted Average Price Per Share
Outstanding at December 31, 2015:	3,000,000	\$ 1.35
Granted	—	—
Exercised	—	—
Expired	—	—
Outstanding at June 30, 2016	<u>3,000,000</u>	<u>\$ 1.35</u>

Warrants

The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Company's common stock as of June 30, 2016:

Warrants Outstanding			Warrants Exercisable		
Price	Outstanding	Expiration Date	Weighted Price	Exercisable	Weighted Price
\$ 1.35	2,449,630	November 2018 ~ November 2020	\$ 1.35	2,449,630	\$ 1.35
\$ 3.60	1,875,000	December 23, 2018	\$ 3.60	1,875,000	\$ 3.60
	<u>4,324,630</u>		<u>\$ 2.32</u>	<u>4,324,630</u>	<u>\$ 2.32</u>

Warrants to purchase up to 2,449,630 shares of the Company's common stock may be exercised on a cashless basis. The warrants to purchase up to 1,875,000 shares of the Company's common stock cannot be exercised on a cashless basis.

Transactions involving stock warrants issued are summarized as follows:

	Number of Shares	Weighted Average Price Per Share
Outstanding at December 31, 2015:	4,324,630	\$ 2.32
Granted	—	—
Exercised	—	—
Expired	—	—
Outstanding at June 30, 2016	<u>4,324,630</u>	<u>\$ 2.32</u>

Restricted Stock Units ("RSU")

The following table summarizes the restricted stock activity for the six months ended June 30, 2016:

Restricted shares units issued as of January 1, 2016	—
Granted	150,000
Forfeited	—
Total Restricted Shares Issued at June 30, 2016	<u>150,000</u>
Vested at June 30, 2016	—
Unvested restricted shares as of June 30, 2016	<u>150,000</u>

On May 31, 2016, the Company granted 150,000 performance-based, restricted stock units vesting over three years based on the achievement of certain defined annual financial benchmarks, pursuant to terms of employment offered to the Company's newly appointed Chief Financial Officer, effective July 11, 2016. The estimated fair value of the granted restricted stock units of \$156,000 will be recognized over the vesting period(s).

Stock-based compensation expense related to restricted stock units was \$-0- for the three and six months ended June 30, 2016. As of June 30, 2016, the stock-based compensation relating to restricted stock units of \$156,000 remains unamortized and is expected to be amortized over the remaining vesting period of approximately three years.

NOTE 13 — VARIABLE INTEREST ENTITY

Brevard Orthopaedic Spine & Pain Clinic, Inc.

Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operation and Control Agreement (the Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations including the requirement to absorb losses or right to receive economic benefits. The initial term of the Agreement expires on December 31, 2016, with an option by the Company to extend the term until December 31, 2023. The Company issued 3,000,000 options to purchase the Company’s common stock, vesting contingent on The B.A.C.K. Center employees signing employment contracts with First Choice – Brevard.

The Company has determined that The B.A.C.K. Center is a Variable Interest Entity (“VIE”) in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, “Consolidation”. In evaluating whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers the purpose for which the VIE was created, the importance of each of the activities in which it is engaged and the Company’s decision-making role, if any, in those activities that significantly determine the entity’s economic performance as compared to other economic interest holders.

This evaluation requires consideration of all facts and circumstances relevant to decision-making that affects the entity’s future performance and the exercise of professional judgment in deciding which decision-making rights are most important.

In determining whether the Company has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, the Company evaluates all of its economic interests in the entity, regardless of form (debt, equity, management and servicing fees, and other contractual arrangements). This evaluation considers all relevant factors of the entity’s structure, including: the entity’s capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have potential to be economically significant.

The evaluation of each of these factors in reaching a conclusion about the potential significance of the Company’s economic interests is a matter that requires the exercise of professional judgment. The assets of The B.A.C.K. Center can only be used to settle obligations of the VIE, additionally, creditors of The B.A.C.K. Center do not have recourse against the general credit of the primary beneficiary.

The table below summarizes the assets and liabilities associated with The B.A.C.K. Center as of June 30, 2016 and as of December 31, 2015:

	June 30, 2016	December 31, 2015
Current assets:		
Cash	\$ 975,568	\$ 996,986
Accounts receivable	4,061,556	3,727,419
Other current assets	1,199,553	819,757
Total current assets	6,236,677	5,544,162
Property and equipment, net	57,581	60,978
Other assets	22,005	18,231
Total assets	\$ 6,316,263	\$ 5,623,371
Current liabilities:		
Accounts payable and accrued liabilities	\$ 1,973,349	\$ 1,877,690
Due to First Choice Healthcare Solutions, Inc.	2,191,881	1,729,882
Other current liabilities	681,273	427,229
Total current liabilities	4,846,503	4,034,801
Long term debt	1,608,446	1,727,256
Total liabilities	6,454,949	5,762,057
Non-controlling interest	(138,686)	(138,686)
Total liabilities and deficit	\$ 6,316,263	\$ 5,623,371

Total revenues from The B.A.C.K. Center were \$3,562,161 and \$6,955,158 for the three and six months ended June 30, 2016. Related expenses consisted primarily of salaries and benefits of \$1,762,710 and \$3,220,621, general and administrative expenses of \$1,624,249 and \$3,206,042, depreciation of \$5,701 and \$11,216, interest and financing costs of \$3,947 and \$7,394; and other income of \$44,506 and \$101,231 for the three and six months ended June 30, 2016, respectively. (See Note 15 – Segment Reporting)

Crane Creek Surgery Center

Effective October 1, 2015, the Company, through its then newly formed wholly owned subsidiary, CCSC Holdings, Inc., acquired a 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of \$560,000 comprised of \$140,000 cash and a promissory note for \$420,000 which bore 8% interest per annum, matures April 15, 2016 and was personally guaranteed by the Company’s Chief Executive Officer. The promissory note was paid in full on April 15, 2016.

In connection with the investment, the Company is entitled to 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crane Creek.

The Company has determined that Crane Creek is a Variable Interest Entity (“VIE”) in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, “Consolidation”. In evaluating whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers the purpose for which the VIE was created, the importance of each of the activities in which it is engaged and the Company’s decision-making role, if any, in those activities that significantly determine the entity’s economic performance as compared to other economic interest holders.

This evaluation requires consideration of all facts and circumstances relevant to decision-making that affects the entity’s future performance and the exercise of professional judgment in deciding which decision-making rights are most important.

In determining whether the Company has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, the Company evaluates all of its economic interests in the entity, regardless of form (debt, equity, management and servicing fees, and other contractual arrangements). This evaluation considers all relevant factors of the entity’s structure, including: the entity’s capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have potential to be economically significant. The evaluation of each of these factors in reaching a conclusion about the potential significance of the Company’s economic interests is a matter that requires the exercise of professional judgment.

The assets of Crane Creek can only be used to settle obligations of the VIE, additionally, creditors of the Crane Creek do not have recourse against the general credit of the primary beneficiary.

The table below summarizes the assets and liabilities associated with the Crane Creek as of June 30, 2016 and December 31, 2015:

	June 30, 2016	December 31, 2015
Current assets:		
Cash	\$ 324,823	\$ 559,318
Accounts receivable	1,263,191	816,889
Total current assets	1,588,014	1,376,207
Property and equipment, net	677,498	712,830
Goodwill	899,465	899,465
Total assets	<u>\$ 3,164,977</u>	<u>\$ 2,988,502</u>
Current liabilities:		
Accounts payable and accrued liabilities	\$ 305,644	\$ 441,368
Other current liabilities	251,588	251,588
Total current liabilities	557,232	692,956
Deferred rent	532,752	532,752
Total liabilities	1,089,984	1,225,708
Equity-First Choice Healthcare Solutions, Inc.	829,998	705,118
Non-controlling interest	1,244,995	1,057,676
Total liabilities and deficit	<u>\$ 3,164,977</u>	<u>\$ 2,988,502</u>

Total revenues from Crane Creek were \$1,446,053 and \$2,717,361 for the three and six months ended June 30, 2016. Related expenses consisted primarily of salaries and benefits of \$314,056 and \$607,393, practice supplies and operating expenses of \$830,261 and \$1,539,907, general and administrative expenses of \$125,893 and \$235,168, depreciation of \$(22,244) and \$49,012, interest expense of \$1,361 and \$10,087, gain on sale of equipment of \$23,378 and \$23,378 and miscellaneous income of \$1,556 and \$2,938 for the three and six months ended June 30, 2016, respectively. (See Note 15 – Segment Reporting)

NOTE 14 — NON-CONTROLLING INTEREST

Effective May 1, 2015, the Company, through its then newly formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operation and Control Agreement (the Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company has sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations, including the requirement to absorb losses or right to receive economic benefits. The initial term of the Agreement expires on December 31, 2016 with an option by the Company to extend the term until December 31, 2023.

A reconciliation of the non-controlling income attributable to the Company:

Net loss attributable to non-controlling interest for the three months ended June 30, 2016:

Net income	\$	133,258
Average Non-controlling interest percentage of profit/losses		-0-%
Net income attributable to the non-controlling interest	<u>\$</u>	<u>-0-</u>

Net loss attributable to non-controlling interest for the six months ended June 30, 2016:

Net income	\$	461,999
Average Non-controlling interest percentage of profit/losses		-0-%
Net income attributable to the non-controlling interest	<u>\$</u>	<u>-0-</u>

The following table summarizes the changes in non-controlling interest for the six months ended June 30, 2016:

Balance, December 31, 2015	\$	(138,686)
Transfer (to) from the non-controlling interest as a result of change in ownership		—
Net income attributable to the non-controlling interest		—
Balance, June 30, 2016	<u>\$</u>	<u>(138,686)</u>

Effective October 1, 2015, the Company, through its then newly formed wholly owned subsidiary, CCSC Holdings, Inc., acquired a 40% interest in Crane Creek Surgery Center (“Crane Creek”) in exchange for an investment of \$560,000 comprised of \$140,000 cash and a promissory note for \$420,000 which bears 8% interest per annum, matures April 15, 2016 and is personally guaranteed by the Company’s Chief Executive Officer. This promissory note was paid in full on April 15, 2016. In connection with the investment, the Company is entitled to 51% voting rights for all decisions that most significantly affect the economic performance of Crane Creek. The 40% equity interest acquired entitles the Company to 40% of the profit or loss of Crane Creek.

A reconciliation of the non-controlling income attributable to the Company:

Net income attributable to non-controlling interest for the three months ended June 30, 2016:

Net income	\$	223,021
Average Non-controlling interest percentage of profit/losses		60%
Net income/loss attributable to the non-controlling interest	<u>\$</u>	<u>133,812</u>

Net income attributable to non-controlling interest for the six months ended June 30, 2016:

Net income	\$ 312,198
Average non-controlling interest percentage of profit/losses	60%
Net income/loss attributable to the non-controlling interest	<u>\$ 187,319</u>

The following table summarizes the changes in non-controlling interest for the six months ended June 30, 2016:

Balance, December 31, 2015	\$ 1,057,676
Transfer (to) from the non-controlling interest as a result of change in ownership	—
Net income attributable to the non-controlling interest	187,319
Balance, June 30, 2016	<u>\$ 1,244,995</u>

NOTE 15 — SEGMENT REPORTING

The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has three reportable segments: FCID Medical, Inc., The B.A.C.K. Center and CCSC Holdings, Inc.

All reportable segments derive revenue for medical services provided to patients; and The B.A.C.K Center additionally derives revenue for subleasing space within its building and medical services provided to patients. With the aforementioned sale and leaseback of Marina Towers on March 31, 2016, the Company will no longer report segmented rental revenue received from third party Marina Tower tenants under the segment heading “Marina Towers.” Rather, the Company has consolidated rental revenue received from third party tenants of Marina Towers under the “Corporate” segment for both the 2016 and 2015 comparable reporting periods; and will continue to do so hereafter.

Information concerning the operations of the Company’s reportable segments is as follows:

Summary Statement of Operations for the three months ended June 30, 2016:

	FCID Medical	The B.A.C.K. Center	CCSC	Corporate	Intercompany Eliminations	Total
Revenue:						
Net patient service revenue	\$2,377,400	\$ 3,199,809	\$1,446,053	\$ —	\$ —	\$7,023,262
Rental revenue	—	362,352	—	267,486	—	629,838
Total revenue	<u>2,377,400</u>	<u>3,562,161</u>	<u>1,446,053</u>	<u>267,486</u>	<u>—</u>	<u>7,653,100</u>
Operating expenses:						
Salaries & benefits	871,446	1,762,710	314,056	190,830	—	3,139,042
Other operating expenses	327,576	—	830,261	415,539	—	1,573,376
General and administrative	321,823	1,624,249	125,893	463,776	—	2,535,741
Depreciation and amortization	67,907	5,701	(22,244)	85,436	—	136,800
Total operating expenses	<u>1,588,752</u>	<u>3,392,660</u>	<u>1,247,966</u>	<u>1,155,581</u>	<u>—</u>	<u>7,384,959</u>
Net income (loss) from operations:	788,648	169,501	198,087	(888,095)	—	268,141
Interest income (expense)	(54,805)	(3,618)	(1,361)	8,731	—	(51,053)
Amortization of financing costs	—	(329)	—	—	—	(329)
Gain on sale of property	—	—	23,378	—	—	23,378
Other income (expense)	—	44,506	1,556	750	—	46,812
Net Income (loss) before income taxes:	733,843	210,060	221,660	(878,614)	—	286,949
Income taxes	—	—	—	—	—	—
Net income (loss)	733,843	210,060	221,660	(878,614)	—	286,949
Non-controlling interest	—	—	(133,812)	—	—	(133,812)
Net income (loss) attributable to First Choice Healthcare Solutions	<u>\$ 733,843</u>	<u>\$ 210,060</u>	<u>\$ 87,848</u>	<u>\$ (878,614)</u>	<u>\$ —</u>	<u>\$ 153,137</u>

Summary Statement of Operations for the three months ended June 30, 2015:

	FCID Medical	The B.A.C.K. Center	Corporate	Intercompany Eliminations	Total
Revenue:					
Net patient service revenue	\$ 1,873,219	\$ 1,930,820	\$ —	\$ —	\$ 3,804,039
Rental revenue	—	256,132	375,512	(111,368)	520,276
Total revenue	<u>1,873,219</u>	<u>2,186,952</u>	<u>375,512</u>	<u>(111,368)</u>	<u>4,324,315</u>
Operating expenses:					
Salaries & benefits	781,064	1,250,618	93,799	—	2,125,481
Other operating expenses	564,847	—	109,943	(111,368)	563,422
General and administrative	319,237	917,456	413,177	—	1,649,870
Depreciation and amortization	66,745	3,223	74,449	—	144,417
Total operating expenses	<u>1,731,893</u>	<u>2,171,297</u>	<u>691,368</u>	<u>(111,368)</u>	<u>4,483,190</u>
Net income (loss) from operations:	141,326	15,655	(315,856)	—	(158,875)
Interest expense	(68,798)	(7,264)	(282,932)	—	(358,994)
Amortization of financing costs	(4,233)	(659)	(14,337)	—	(19,229)
Other income (expense)	—	19,150	21,219	—	40,369
Net Income (loss):	68,295	26,882	(591,906)	—	(496,729)
Income taxes	—	—	—	—	—
Net income (loss)	<u>\$ 68,295</u>	<u>\$ 26,882</u>	<u>\$ (591,906)</u>	<u>\$ —</u>	<u>\$ (496,729)</u>

Summary Statement of Operations for the six months ended June 30, 2016:

	FCID Medical	The B.A.C.K. Center	CCSC	Corporate	Intercompany Eliminations	Total
Revenue:						
Net patient service revenue	\$4,686,335	\$ 6,234,707	\$2,717,361	\$ —	\$ —	\$13,638,403
Rental revenue	—	720,451		695,732	(159,733)	1,256,450
Total revenue	<u>4,686,335</u>	<u>6,955,158</u>	<u>2,717,361</u>	<u>695,732</u>	<u>(159,733)</u>	<u>14,894,853</u>
Operating expenses:						
Salaries & benefits	1,700,666	3,220,621	607,393	390,931	—	5,919,611
Other operating expenses	858,983	—	1,539,907	521,493	(159,733)	2,760,650
General and administrative	683,626	3,206,042	235,168	816,782	—	4,941,618
Depreciation and amortization	134,699	11,216	49,012	240,823	—	435,750
Total operating expenses	<u>3,377,974</u>	<u>6,437,879</u>	<u>2,431,480</u>	<u>1,970,029</u>	<u>(159,733)</u>	<u>14,057,629</u>
Net income (loss) from operations:	1,308,361	517,279	285,881	(1,274,297)	—	837,224
Interest income (expense)	(111,623)	(6,077)	(10,087)	(104,401)	—	(232,188)
Amortization of financing costs	—	(1,317)	—	(14,337)	—	(15,654)
Gain on sale of property	—	—	23,378	9,188,968	—	9,212,346
Other income (expense)	—	101,231	2,938	1,500	—	105,669
Net Income (loss) before income taxes:	1,196,738	611,116	302,110	7,797,433	—	9,907,397
Income taxes	—	—	—	—	—	—
Net income (loss)	1,196,738	611,116	302,110	7,797,433	—	9,907,397
Non-controlling interest	—	—	(187,319)	—	—	(187,319)
Net income (loss) attributable to First Choice Healthcare Solutions	<u>\$1,196,738</u>	<u>\$ 611,116</u>	<u>\$ 114,791</u>	<u>\$ 7,797,433</u>	<u>\$ —</u>	<u>\$ 9,720,078</u>

Summary Statement of Operations for the six months ended June 30, 2015:

	FCID Medical	The B.A.C.K. Center	Corporate	Intercompany Eliminations	Total
Revenue:					
Net patient service revenue	\$ 4,113,283	\$ 1,930,820	\$ —	\$ —	\$ 6,044,103
Rental revenue	—	256,132	750,833	(221,586)	785,379
Total revenue	4,113,283	2,186,952	750,833	(221,586)	6,829,482
Operating expenses:					
Salaries & benefits	1,618,051	1,250,618	202,932	—	3,071,601
Other operating expenses	1,023,219	—	213,274	(221,586)	1,014,907
General and administrative	610,396	917,456	675,302	—	2,203,154
Depreciation and amortization	133,260	3,223	148,443	—	284,926
Total operating expenses	3,384,926	2,171,297	1,239,951	(221,586)	6,574,588
Net income (loss) from operations:	728,357	15,655	(489,118)	—	254,894
Interest expense	(120,582)	(7,264)	(594,292)	—	(722,138)
Amortization of financing costs	(10,582)	(659)	(28,674)	—	(39,915)
Other income (expense)	—	19,150	21,969	—	41,119
Net Income (loss):	597,193	26,882	(1,090,115)	—	(466,040)
Income taxes	—	—	—	—	—
Net income (loss)	\$ 597,193	\$ 26,882	\$ (1,090,115)	\$ —	\$ (466,040)

Selected financial data:

	FCID Medical	The B.A.C.K. Center	CCSC	Corporate	Intercompany Eliminations	Total
Assets:						
At June 30, 2016:	\$5,476,146	\$6,316,264	\$3,192,413	\$9,542,881	\$ —	\$24,527,704
At December 31, 2015:	\$4,391,192	\$5,623,370	\$3,013,011	\$9,596,415	\$ —	\$22,623,988
Assets acquired						
Three months ended June 30, 2016	\$ 6,668	\$ 5,703	\$ 11,063	\$ —	\$ —	\$ 23,434
Three months ended June 30, 2015	\$ 1,999	\$ —	\$ —	\$ 29,781	\$ —	\$ 31,780
Six months ended June 30, 2016	\$ 56,561	\$ 7,819	\$ 35,303	\$ 49,824	\$ —	\$ 149,507
Six months ended June 30, 2015	\$ 3,656	\$ —	\$ —	\$ 36,409	\$ —	\$ 40,065

NOTE 16 - COMMITMENTS AND CONTINGENCIES

Litigation – Health First Management

The B.A.C.K. Center has a claim filed in Brevard County, Florida Circuit Court against Health First Management, Inc. due to a contract dispute. A counterclaim was filed against the Company. The case has been litigated for a substantial amount of time and a trial is anticipated to take place within the next 12 months. The Company has vigorously defended against the counterclaim. The Company has accrued a possible loss contingency of approximately \$118,000 during the year ended December 31, 2015. As of June 30, 2016, there has been no change to the status of the litigation.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

Operating leases

The B.A.C.K. Center leases office space under various non-cancelable operating leases that expire at various dates through June 2026. Terms of the lease agreements provide for rental payments ranging from approximately \$4,200 to \$200,000 per month. Certain leases include charges for sales and real estate taxes and a proration of common area maintenance expenses. Under generally accepted accounting principles (GAAP), all rental payments, including fixed rent increases, are recognized on a straight-line basis over the life of the lease. The GAAP-based rent expense and the actual lease payments are reflected as deferred rent on the accompanying balance sheet. From the date of the Operation and Control Agreement through December 31, 2015, lease expense amounted to \$2,360,986.

The following is a schedule of future minimum lease payments for all non-cancelable operating leases for each of the next five years ending December 31 and thereafter:

Six months ended December 31, 2016	\$	1,747,273
Year ended December 31, 2017		3,444,197
Year ended December 31, 2018		3,444,209
Year ended December 31, 2019		3,444,221
Year ended December 31, 2020 and thereafter		20,665,648
	\$	36,189,780

For the six months ended June 30, 2016, The B.A.C.K. Center collected \$720,451 in net rental revenue from third party tenants.

Sale/Leaseback

Effective March 31, 2016, the Company leased Marina Towers under a sale/leaseback transaction (See Note 4), via a 10-year absolute triple-net master lease agreement that expires in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions as the primary non-revocable lease term with the exception of rent, which will be adjusted to the prevailing fair market rent at renewal and will escalate in successive years during the extended lease period. The Company does not have any residual interest nor the option to repurchase the facility at the end of the lease term.

The following is a schedule of future minimum lease payments for the non-cancelable operating lease for each of the next five years ending December 31 and thereafter:

Six months ended December 31, 2016	\$	552,338
Year ended December 31, 2017		1,121,245
Year ended December 31, 2018		1,143,670
Year ended December 31, 2019		1,166,543
Year ended December 31, 2020		1,189,874
Year ended December 31, 2021 and thereafter		6,646,044
	\$	11,819,714

For the six months ended June 30, 2016, the Company collected \$535,999 in net rental revenue from third party tenants of Marina Towers .

Guarantees

The B.A.C.K. Center's shareholders and a related party have guaranteed the full and prompt payment of the base rent, the additional rent and any all other sums and charges payable by a tenant, its successors and assigns under the lease, and the full performance and observance of all the covenants, terms, conditions and agreements for one of the above mentioned operating leases.

NOTE 17 – INCOME TAXES

In the first quarter of 2016, effective March 31, 2016, we sold and leased back Marina Towers under a sale/leaseback transaction (See "Gain on Sale of Property and Improvements"). In connection with the sale, the Company reported a gain on sale of the property of \$9,188,968 (GAAP Basis) for the six months ended June 30, 2016. There was a Tax Basis gain of approximate \$9,051,430. The difference between the GAPP Basis and Tax Basis gain was mainly attributable to depreciation. The gain was offset by Net Operation Losses the Company has generated in prior periods, so no income tax was recorded, but an estimated Alternative Minimum Tax liability of \$181,089 was recorded. Offsetting the Alternative Minimum tax recorded is a Deferred Tax Asset of the same amount related to the Alternative Minimum Tax Liability (Alternative Minimum Tax Credit Carryforward). Management believes the Company will utilize the Alternative Minimum Tax Carryforward in future periods, as of the June 30, 2016 reporting period.

The Company's effective tax rate in the second quarter of 2016 is approximately 38.6% See Note 20, *Income Taxes*, in the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2015 for additional information.

NOTE 18 – SUBSEQUENT EVENTS

On July 6, 2016, the Company announced that it appointed Timothy K. Skeldon as its Chief Financial Officer, who assumed this position on July 11, 2016. Upon commencement of his employment, Mr. Skeldon will receive an annual salary of \$250,000 and receive an additional annual bonus of \$25,000 per year for each completed year of employment. Further, he will be granted a total of 150,000 shares of the Company's Common Stock with a three-year vesting schedule. Up to 50,000 shares per year are eligible to vest based on annual revenue and EBITDA benchmarks agreed upon by Mr. Skeldon and the Company. Shares will be issued on a percentage of actual amount achieved. Mr. Skeldon will also be eligible to participate in the Company's health and other benefits on the same terms as other Company executives. Mr. Skeldon succeeds Donald Bittar, who elected to retire from the Chief Financial Officer position, but will provide corporate advisory support on mergers and acquisitions and other strategic business development opportunities and remain as a member of the Board of Directors.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934 (“Exchange Act”). Forward-looking statements reflect the current view about future events. When used in this quarterly report on Form 10-Q, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this quarterly report on Form 10-Q relating to our business strategy, our future operating results, and our liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, the execution of our strategy to grow our business by hiring additional physicians to create Medical Centers of Excellence that fit our defined criteria; evolving healthcare laws and regulations; changes in the rates or methods of third-party reimbursements for medical services; accelerated pace of consolidation in the hospital industry; changes in our medical technology as it relates to our services and procedures; any failures in our information technology systems to protect the privacy and security of protected information and other similar cyber security risks; our ability to raise capital to fund continuing operations; and other factors relating to our industry, our operations and results of operations and any new Medical Centers of Excellence that we may open. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Overview

First Choice Healthcare Solutions, Inc. (“FCHS,” “the Company,” “we,” “our” or “us”) is implementing the second phase of a defined growth strategy aimed at building a network of localized, integrated healthcare delivery platforms in key expansion markets throughout the Southeastern U.S. Our flagship platform in Melbourne, Florida is comprised of non-physician-owned medical centers of excellence, which concentrate on treating patients in the following specialties: Orthopaedics, Spine Surgery, Neurology and Interventional Pain Management; and provide a robust offering of related diagnostic and ancillary services – all centrally located in a geographic region.

Successful implementation of our first phase allowed us to confirm that by integrating the synergistic mix of Orthopaedic, Spine Surgery, Neurology and Interventional Pain specialties with related diagnostic and ancillary services and state-of-the-art equipment and technologies across legacy brick-and-mortar boundaries, we are able to effectively:

- provide patients with direct and convenient access to musculoskeletal and rehabilitative care via our best-in-class team of surgeons, physicians and care specialists, and wide array of ancillary and diagnostic services, which includes, but is not limited to, magnetic resonance imaging (“MRI”), X-ray (“X-ray”), durable medical equipment (“DME”) and rehabilitative care, including physical therapy (“PT”) and occupational therapy (“OT”).
- empower physicians to collaborate as a unified care team, optimizing care coordination and improving patient outcomes;
- advance the quality and cost effectiveness of our patients’ healthcare, thereby achieving faster recoveries at materially reduced cost to payors; and
- achieve strong, sustainable financial performance that serves to create long-term value for our stockholders.

Our goal is to build a network of non-physician-owned and operated Medical Centers of Excellence in diverse locations, primarily throughout the southeastern region of the United States. By centralizing current and future Centers' business management functions, including call center operations, scheduling, billing, compliance, accounting, marketing, advertising, legal, information technology and record-keeping, at our corporate headquarters, we will maintain efficiencies and achieve scales of economies. We believe our structure will enable our staff physicians to focus on the practice of medicine and the delivery of quality care to the patients we serve, as opposed to having their time and attention focused on business administration responsibilities. We currently have 128 employees, including 12 physicians and seven physician assistants.

Our Healthcare Services Business

Presently, we own and operate First Choice Medical Group of Brevard, LLC ("First Choice – Brevard, "First Choice Medical Group" or "FCMG"), our multi-specialty Medical Center of Excellence located in Melbourne, Florida. First Choice – Brevard specializes in the delivery of musculoskeletal medicine, via our strategically aligned sub-specialties in Orthopaedics, Neurology and Interventional Pain medicine, coupled with on-site diagnostic and ancillary services, including MRI, X-ray, DME, PT and OT with multiple quality-focused goals centered on enriching our patients' care experiences.

On May 1, 2015, through our wholly-owned subsidiary, TBC Holdings of Melbourne, Inc., we entered into an Operation and Control Agreement (the "Agreement") with Brevard Orthopaedic Spine & Pain Clinic, Inc. ("The B.A.C.K. Center"), a premier Spine, Orthopaedic and Pain practice in Brevard County, Florida. The B.A.C.K. Center operates two medical offices located in Melbourne and Merritt Island, Florida.

On October 1, 2015, through our newly formed wholly-owned subsidiary, CCSC Holdings, Inc., we acquired a 40% interest in Melbourne, Florida-based Crane Creek Surgery Center ("Crane Creek"). Established in 2009, Crane Creek is an AAAHC accredited facility dedicated to delivering excellent, ambulatory surgical care in a convenient, comfortable outpatient environment. The modern 18,000+ square foot facility is located in Melbourne, Florida within the Crane Creek Medical Center building, which is also home to Osler Medical and The B.A.C.K. Center. Crane Creek's facility houses four state-of-the-art operating rooms and a procedure room; with capacity and capability to host 4,000-5,000 orthopaedic, spine, interventional pain and general surgical procedures each year. The other owners of Crane Creek are CCSC TBC Group, LLC ("TBC Group"), owned by Richard Hynes, M.D., FASC and Devin Datta, M.D.; and Blue Chip Surgical Center Partners, which develops and manages 17 world class ambulatory surgery centers across the United States. Dr. Hynes and Dr. Datta are both affiliated with The B.A.C.K. Center. Together, CCSC Holdings and TBC Group own 75% interest in Crane Creek. In accordance with the Crane Creek Restated and Amended Operating Agreement, CCSC Holdings will exercise sufficient control over the business of Crane Creek that will allow First Choice to treat it as a variable interest entity, effective October 1, 2015. As a result, First Choice will include the financial results of Crane Creek in its consolidated financial statements in accordance with generally accepted accounting principles as if it were a wholly-owned subsidiary. Dr. Hynes has been appointed as President of Crane Creek's Medical Board and as Medical Director.

Our Real Estate Business

FCID Holdings, Inc. ("FCID Holdings") is our wholly owned subsidiary, which operates our real estate interests. Up until its sale in March 2016, FCID Holdings had one real estate holding, Marina Towers, LLC, a 78,000 square foot, Class A, six-story building located on the Indian River in Melbourne, Florida. In addition to housing our corporate headquarters and FCMG, the building, which averages 95% annual occupancy, also leases approximately 48,698 square feet of commercial office space to third party tenants. In addition, beginning May 1, 2015, TBC Holdings of Melbourne, Inc., through The B.A.C.K. Center, subleases approximately 34,480 square feet of commercial office space to third party tenants.

On March 31, 2016, we completed the sale of Marina Towers to Global Medical REIT Inc. for a purchase price of \$15.45 million. In addition, our wholly owned subsidiary, Marina Towers, LLC, leased back the entire facility via a 10-year absolute triple-net master lease agreement that will expire in 2026 and be renewable for two five-year periods on the same terms and conditions as the primary lease term with the exception of rent, which will be adjusted to the prevailing market rent at renewal and will escalate in successive years during the extended lease period.

New Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company's financial position, results of operations or cash flows.

Results of Operations for the Three Months Ended June 30, 2016 and 2015

Revenues

Total revenues increased 77% to \$7,653,100 for the three months ended June 30, 2016 as compared to revenues of \$4,324,315 for the same period in the prior year. The increase is primarily attributed to the addition on May 1, 2015 of Brevard Orthopaedic Spine & Pain Clinic, Inc. ("The B.A.C.K. Center") and on October 1, 2015 of Crane Creek Surgical Center ("Crane Creek"), which contributed revenues of \$3,562,161 and \$1,446,053, respectively, for the quarter comprised of additional patient services revenue of \$4,645,862 and rental revenue of \$362,352. Patient services revenue generated by First Choice Medical Group ("FCMG") increased by \$504,181, or 27%, after factoring provision for doubtful accounts. Rental revenue increased by \$109,562, totaling \$629,838 and \$520,276 for the three months ended June 30, 2016 and 2015, respectively, primarily due to the addition of rental revenue from The B.A.C.K. Center.

The provision for doubtful accounts during the second quarter of 2016 totaled \$267,194. We adopted the provisions of ASU 2011-07 in 2014, which requires that healthcare entities change the presentation of the statement of operations by reclassifying the provision for doubtful accounts from an operating expense to a deduction from patient service revenues. All periods presented have been reclassified in accordance with ASU 2011-07.

Operating Expenses

Operating expenses include the following:

	Three Months Ended June 30, 2016	Three Months Ended June 30, 2015
Salaries and benefits	\$ 3,139,042	\$ 2,125,481
Other operating expenses	1,573,376	563,422
General and administrative	2,535,741	1,649,870
Depreciation and amortization	136,800	144,417
Total operating expenses	<u>\$ 7,384,959</u>	<u>\$ 4,483,190</u>

The major components of operating expenses include practice salaries and benefits, practice supplies and other operating costs, depreciation and general and administrative expenses, which included legal, accounting and professional fees associated with being a public entity.

Salaries and benefits increased 48% to \$3,139,042 for the three months ended June 30, 2016, compared to \$2,125,481 for the three months ended June 30, 2015. The increase was primarily due to the addition on May 1, 2015 of The B.A.C.K. Center and October 1, 2015 of Crane Creek, which represented an additional \$826,148 in the reporting period. The existing segments netted an increase of \$187,413 as compared to 2015. Other operating expenses increased 179% to \$1,573,376 from \$563,422 due to the increase in patient service volume from 2015 to 2016 with the added facilities.

General and administrative expenses for the three months ended June 30, 2016 increased 54% to \$2,535,741, up from \$1,649,870. The increase was largely attributable adding The B.A.C.K. Center and Crane Creek, adding \$832,686 in costs. We believe that each additional sale or service and corresponding gross profit of such sale or service has minimal incremental offsetting operating expenses. Thus, additional sales could contribute to profit at a higher rate of return on sales as a result of not needing to expand operating expenses at the same pace as sales.

Depreciation and amortization decreased 5% from \$144,417 reported for the three months ended June 30, 2015 to \$136,800 reported for the three months ended June 30, 2016. The decrease is primarily due to the sale/leaseback of our office building net with an increase from our two additional operating segments.

Net Income from Operations

The income from operations for the three months ended June 30, 2016 increased 269% to \$268,141, which compared to loss from operations of \$(158,875) for the same period in the prior year. Notwithstanding non-cash expenses totaling \$657,456 for the three months ended June 30, 2016, which included stock-based compensation, depreciation and amortization, income from operations totaled \$925,597. This compared to income from operations of \$137,076 after factoring \$295,951 in non-cash stock-based compensation, depreciation and amortization recorded for the three months ended June 30, 2015.

Gain on Sale of Property and Improvements

During the three months ended June 30, 2016, we sold equipment for a net gain of \$23,378 as compared to \$-0- for the same period last year.

Interest Expense

Interest expense decreased 86% to \$51,053 for the three months ended June 30, 2016, which compared to \$358,994 for the three months ended June 30, 2015. The decrease primarily is due to payoff of our Marina Towers mortgage and conversions of our convertible notes payable to Hillair Capital Investments, LP in 2015 as compared to the same period last year.

Net Income (Loss)

As a result of all the above, we reported net income of \$153,137 for the three months ended June 30, 2016, representing a significant improvement over a net loss of \$(496,729) reported for the same three-month period in the prior year.

Segment Results

The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments.

The following are the revenues, operating expenses and net loss by segment for the three months ended June 30, 2016 and 2015, respectively.

With the aforementioned sale and leaseback of Marina Towers on March 31, 2016, the Company will no longer report segmented rental revenue received from third party Marina Tower tenants under the segment heading “Marina Towers.” Rather, the Company has consolidated rental revenue received from third party tenants of Marina Towers under the “Corporate” segment for both the 2016 and 2015 comparable reporting periods; and will continue to do so hereafter. The significant fluctuations in the line items are described above.

For the Three Months Ended June 30, 2016:

	FCID Medical	The B.A.C.K. Center	CCSC	Corporate	Intercompany Eliminations	Total
Revenue:						
Net patient service revenue	\$2,377,400	\$3,199,809	\$1,446,053	\$ —	\$ —	\$7,023,262
Rental revenue	—	362,352	—	267,486	—	629,838
Total revenue	2,377,400	3,562,161	1,446,053	267,486	—	7,653,100
Total operating expenses	1,588,752	3,392,660	1,247,966	1,155,581	—	7,384,959
Net income (loss) from operations:	788,648	169,501	198,087	(888,095)	—	268,141

For the Three Months Ended June 30, 2015:

	FCID Medical	The B.A.C.K. Center	Corporate	Intercompany Eliminations	Total
Revenue:					
Net patient service revenue	\$ 1,873,219	\$ 1,930,820	\$ —	\$ —	\$ 3,804,039
Rental revenue	—	256,132	375,512	(111,368)	520,276
Total revenue	1,873,219	2,186,952	375,512	(111,368)	4,324,315
Total operating expenses	1,731,893	2,171,297	691,368	(111,368)	4,483,190
Net income (loss) from operations:	141,326	15,655	(315,856)	—	(158,875)

Results of Operations for the Six Months Ended June 30, 2016 and 2015

Revenues

Total revenues increased 118% to \$14,894,853 for the six months ended June 30, 2016 as compared to revenues of \$6,829,482 for the same period in the prior year. The increase is primarily attributed to the addition on May 1, 2015 of Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”) and on October 1, 2015 of Crane Creek Surgical Center (“Crane Creek”), which contributed revenues of \$6,955,158 and \$2,717,361, respectively, for the six months comprised of additional patient services revenue of \$8,952,068 and rental revenue of \$720,451. Patient services revenue generated by First Choice Medical Group (“FCMG”) increased by \$573,052 or 14%, after factoring provision for doubtful accounts. Rental revenue increased by \$471,071, totaling \$1,256,450 and \$785,379 for the six months ended June 30, 2016 and 2015, respectively, primarily due to the addition of rental revenue from The B.A.C.K. Center.

The provision for doubtful accounts during the first six months of 2016 totaled \$529,718. We adopted the provisions of ASU 2011-07 in 2014, which requires that healthcare entities change the presentation of the statement of operations by reclassifying the provision for doubtful accounts from an operating expense to a deduction from patient service revenues. All periods presented have been reclassified in accordance with ASU 2011-07.

Operating Expenses

Operating expenses include the following:

	Six Months Ended June 30, 2016	Six Months Ended June 30, 2015
Salaries and benefits	\$ 5,919,611	\$ 3,071,601
Other operating expenses	2,760,650	1,014,907
General and administrative	4,941,618	2,203,154
Depreciation and amortization	435,750	284,926
Total operating expenses	\$ 14,057,629	\$ 6,574,588

The major components of operating expenses include practice salaries and benefits, practice supplies and other operating costs, depreciation and general and administrative expenses, which included legal, accounting and professional fees associated with being a public entity.

Salaries and benefits increased 93% to \$5,919,611 for the six months ended June 30, 2016, compared to \$3,071,601 for the six months ended June 30, 2015. The increase was primarily due to the addition on May 1, 2015 of The B.A.C.K. Center and October 1, 2015 of Crane Creek, which represented an additional \$2,577,396 in the reporting period. The existing segments netted an increase of \$270,614 as compared to 2015. Other operating expenses increased 172% to \$2,760,650 from \$1,014,907 due to the increase in patient service volume from 2015 to 2016 with the added facilities.

General and administrative expenses for the six months ended June 30, 2016 increased 124% to \$4,941,618, up from \$2,203,154. The increase was largely attributable adding The B.A.C.K. Center and Crane Creek, adding \$2,523,754 in costs. We believe that each additional sale or service and corresponding gross profit of such sale or service has minimal incremental offsetting operating expenses. Thus, additional sales could contribute to profit at a higher rate of return on sales as a result of not needing to expand operating expenses at the same pace as sales.

Depreciation and amortization increased 5% from \$284,926 for the six months ended June 30, 2015 to \$435,750 for the six months ended June 30, 2016. The increase is primarily due to the addition of The B.A.C.K. Center and Crane Creek segments.

Net Income from Operations

The income from operations for the six months ended June 30, 2016 increased 228% to \$837,224, which compared to income from operations of \$254,894 for the same period in the prior year. Notwithstanding non-cash expenses totaling \$1,315,555 for the six months ended June 30, 2016, which included stock-based compensation, depreciation and amortization, income from operations totaled \$2,152,779. This compared to income from operations of \$784,828 after factoring \$334,433 in non-cash stock-based compensation, depreciation and amortization recorded for the six months ended June 30, 2015.

Gain on Sale of Property and Improvements

During the six months ended June 30, 2016, we sold equipment for a net gain of \$23,378 as compared to \$-0- for the same period last year.

Effective March 31, 2016, we sold and leased back Marina Towers under a sale/leaseback transaction via a 10-year absolute triple-net master lease agreement that expires in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions as the primary non-revocable lease term with the exception of rent, which will be adjusted to the prevailing fair market rent at renewal and will escalate in successive years during the extended lease period. In connection with the sale, we reported a gain on sale of property of \$9,188,968 for the six months ended June 30, 2016.

Interest Expense

Interest expense decreased 68% to \$232,188 for the six months ended June 30, 2016, which compared to \$722,138 for the six months ended June 30, 2015. The decrease primarily is due to payoff of our Marina Towers mortgage and conversions of our convertible notes payable with Hillair Capital Investments, LP in 2015 as compared to the same period last year.

Net Income (Loss)

As a result of all the above, we reported net income of \$9,720,078 for the six months ended June 30, 2016, representing a significant improvement over net loss of \$(466,040) reported for the same three-month period in the prior year.

Segment Results

The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments.

The following are the revenues, operating expenses and net loss by segment for the six months ended June 30, 2016 and 2015, respectively. With the aforementioned sale and leaseback of Marina Towers on March 31, 2016, the Company will no longer report segmented rental revenue received from third party Marina Tower tenants under the segment heading “Marina Towers.” Rather, the Company has consolidated rental revenue received from third party tenants of Marina Towers under the “Corporate” segment for both the 2016 and 2015 comparable reporting periods; and will continue to do so hereafter. The significant fluctuations in the line items are described above.

For the Six Months Ended June 30, 2016:

	FCID Medical	The B.A.C.K. Center	CCSC	Corporate	Intercompany Eliminations	Total
Revenue:						
Net patient service revenue	\$4,686,335	\$6,234,707	\$2,717,361	\$ —	\$ —	\$13,638,403
Rental revenue	—	720,451	—	695,732	(159,733)	1,256,450
Total revenue	4,686,335	6,955,158	2,717,361	695,732	(159,733)	14,894,853
Total operating expenses	3,377,974	6,437,879	2,431,480	1,970,029	(159,733)	14,057,629
Net income (loss) from operations:	1,308,361	517,279	285,881	(1,274,297)	—	837,224

For the Six Months Ended June 30, 2015:

	FCID Medical	The B.A.C.K. Center	Corporate	Intercompany Eliminations	Total
Revenue:					
Net patient service revenue	\$ 4,113,283	\$ 1,930,820	\$ —	\$ —	\$ 6,044,103
Rental revenue	—	256,132	750,833	(221,586)	785,379
Total revenue	4,113,283	2,186,952	750,833	(221,586)	6,829,482
Total operating expenses	3,384,926	2,171,297	1,239,951	(221,586)	6,574,588
Net income (loss) from operations:	728,357	15,655	(489,118)	—	254,894

Liquidity and Capital Resources

As of June 30, 2016, we had cash of \$7,785,602 and accounts receivables totaling \$8,369,428. This compared to cash of \$1,594,998, restricted cash of \$359,414 and accounts receivable of \$6,623,894 as of the end of 2015.

The Marina Towers building is 95% occupied. We believe that our current positive cash balance, along with continued execution of our Company’s business development plan, will allow us to further improve our working capital; and that we will have sufficient capital resources to meet projected cash flow requirements through the date that is one year plus a day from the filing date of this report. However, there can be no assurance that we will be successful in fully executing our business development plan.

Net cash used in our operating activities for the six months ended June 30, 2016 totaled \$1,274,163, which compared to net cash provided by our operations for the six months ended June 30, 2015 of \$69,994. The decrease in cash provided was due primarily to net income of \$9,907,397 for the current period as compared to net loss of \$(466,040) for the six months ended June 30, 2015, offset by stock-based compensation of \$334,433, payment of the non-cash loan extension of \$92,000, bad debt expense of \$529,718 and depreciation and amortization of \$451,404, net with the gain on the sale of property of \$9,212,346 for the six months ended June 30, 2016. This compared to a \$796,849 aggregate change for the same period last year. In addition, our operating assets increased by \$2,232,334 and \$477,421 for the six months ended June 30, 2016 and 2015, respectively; and our operating liabilities decreased in 2016 by \$1,144,435 as compared to increasing by \$216,606 for the six months ended June 30, 2015.

Net cash flows provided by investing activities was \$14,963,990 for the six months ended June 30, 2016, compared to \$639,608 provided by investing activities for the six months ended June 30, 2015. In 2016, we received \$15,068,497 net proceeds from the sale of Marina Towers and \$45,000 for the sale of equipment. In 2015, we incorporated \$679,673 cash from a variable interest entity. Purchases of equipment were \$149,507 and \$40,065 for the six months ended June 30, 2016 and 2015, respectively, due to less cash spent on the purchase of equipment in 2015 compared to the current year.

Cash flows used in financing activities was \$7,499,223 for six months ended June 30, 2016, compared to net cash provided by financing activities of \$65,876 for the six months ended June 30, 2015. The cash flows provided by (used in) financing activities were the result of:

	Six Months ended June 30, 2016	Six Months ended June 30, 2015
(Repayments) proceeds from advances	\$ (43,082)	\$ 129,000
Proceeds from lines of credit	372,636	355,656
Net payments on notes payable	(7,828,777)	(418,780)
Net cash (used in) provided by financing activities	<u>\$ (7,499,223)</u>	<u>\$ 65,876</u>

On March 31, 2016, in connection with the sale/leaseback transaction of Marina Towers, we paid off the outstanding mortgage balance due of \$7,223,771.

Currently, we are actively engaged in identifying and pursuing discussions with prospective acquisitions and/or implementation of operation and management agreements that qualify as variable interest entities in accordance with generally accepted accounting practices in key target markets — with those being largely in the southeastern U.S. Over the next 12 months, we expect to incur significant capital costs to further develop and expand our medical operations. We plan to add another medical center of excellence and purchase additional diagnostic equipment for our operations. We expect to need additional capital of approximately \$4-6 million to fund the development and expansion of our operations over the next 12 months. However, there can be no assurance that we will be able to negotiate acceptable terms for, or find suitable candidates for, such acquisition.

There can be no assurance that our cash flow will increase in the near future from anticipated new business activities, or that revenues generated from our existing operations will be sufficient to allow us to continue to pursue new customer programs or profitable ventures.

Off Balance Sheet Arrangements

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies and Estimates

Our unaudited condensed consolidated financial statements have been prepared by management in accordance with U.S. GAAP.

Recently Issued Accounting Pronouncements

There were various updated recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company's financial position, results of operations or cash flows.

Management does not believe that any other recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Inflation

The effect of inflation on our revenue and operating results was not significant.

Climate Change

We believe that neither climate change, nor government regulations related to climate change, have had, or are expected to have, any material effect on our operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a smaller reporting company, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Pursuant to Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting (as such term is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 30, 2016, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

Item 1. Legal Proceedings

The B.A.C.K. Center has a claim filed in Brevard County, Florida Circuit Court against Health First Management, Inc. due to a contract dispute. A counterclaim was filed against the Company. The case has been litigated for a substantial amount of time and a trial is anticipated to take place within the next 12 months. The Company has vigorously defended against the counterclaim. The Company has accrued a possible loss contingency of approximately \$118,000 during the year ended December 31, 2015.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

Item 1A. Risk Factors

There have been no material changes to the Risk Factors reported in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults upon Senior Securities

There has been no default in the payment of principal, interest, sinking or purchase fund installment, or any other material default, with respect to any indebtedness of our Company.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

- 31.1 Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).*
- 31.2 Certification by the Principal Accounting Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).*
- 32.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
- 32.2 Certification by the Principal Accounting Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

* Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.

FIRST CHOICE HEALTHCARE SOLUTIONS, INC.

Dated: August 15, 2016

By: /s/ Christian C. Romandetti
Christian C. Romandetti
Chief Executive Officer (Principal Executive Officer)

Dated: August 15, 2016

By: /s/ Timothy K. Skeldon
Timothy K. Skeldon
Chief Financial Officer (Principal Accounting Officer)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Christian C. Romandetti, certify that:

- 1) I have reviewed this Quarterly Report on Form 10-Q of First Choice Healthcare Solutions, Inc. (the “registrant”);
- 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
- 3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;
- 4) The small business issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
- 5) I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By: /s/ CHRISTIAN C. ROMANDETTI

Christian C. Romandetti
Chief Executive Officer

August 15, 2016

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Timothy K. Skeldon, certify that:

- 1) I have reviewed this Quarterly Report on Form 10-Q of First Choice Healthcare Solutions, Inc. (the “registrant”);
- 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
- 3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
- 5) I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By: /s/ Timothy K. Skeldon
Timothy K. Skeldon
Chief Financial Officer

August 15, 2016

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of First Choice Healthcare Solutions, Inc. (the "Company"), as filed with the U.S. Securities and Exchange Commission on the date hereof (the "Report"), I, Christian C. Romandetti, the Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ CHRISTIAN C. ROMANDETTI

Christian C. Romandetti

Chief Executive Officer

Dated: August 15, 2016

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of First Choice Healthcare Solutions, Inc. (the "Company"), as filed with the U.S. Securities and Exchange Commission on the date hereof (the "Report"), I, Timothy K. Skeldon, the Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 15, 2016

By: /s/ TIMOTHY K. SKELDON
Timothy K. Skeldon
Chief Financial Officer
